HIV/AIDS Research

Report issued on phase 1/2 clinical trials for HIV/AIDS antiretroviral drug

Published in Medical Letter on the CDC and FDA, July 24th, 2005

Harbinger Research LLC, an independent research firm, announced that it has issued a Bird's Eye Report for Amazon Biotech, Inc. (AMZB), a development stage pharmaceutical/biotech company that is focused on the research and development of all-natural drugs for the treatment of HIV and AIDS.

The report provides an in-depth overview of the company's upcoming phase 1/2 clinical trials, and past clinical trials, for its drug candidate AMZ 0026, the HIV and AIDS landscape and market opportunity, the difference between, and importance of, antiretrovirals and immune modulators, as well as the investment opportunity Amazon presents.

The report is available...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-07-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry